BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Search

Argenx SE

Abierto

SectorSalud

533 0.53

Resumen

Variación precio

24h

Actual

Mínimo

523.6

Máximo

534.4

Métricas clave

By Trading Economics

Ingresos

751M

836M

Ventas

730M

1.3B

P/B

Media del Sector

46.72

57.333

BPA

0.72

Margen de beneficio

64.112

Empleados

1,599

EBITDA

37M

126M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

-2.07% downside

Dividendos

By Dow Jones

Próximas Ganancias

8 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-4.3B

32B

Apertura anterior

532.47

Cierre anterior

533

Argenx SE Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

10 abr 2025, 23:44 UTC

Acciones populares

Stocks to Watch: Jacobs Solutions, Argenx

10 abr 2025, 23:39 UTC

Principales Movimientos del Mercado

Argenx ADRs Gain, FDA Approves New Delivery Method of Existing Autoimmune Disease Treatment

Comparación entre iguales

Cambio de precio

Argenx SE Esperado

Precio Objetivo

By TipRanks

-2.07% caída

Estimación a 12 meses

Media 438.33 EUR  -2.07%

Máximo 545 EUR

Mínimo 223 EUR

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Argenx SE Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

5

Comprar

0

Mantener

1

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.